P6244Rapid carotid plaques reversal of PCSK9 inhibitors when added to statins and eicosapentaenoic acid in high risk cardiovascular patients

Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review

“…In the GLAGOV trial that included 968 patients, the PCSK9 inhibitor evolocumab resulted in ~1% reduction of atheroma plaque volume measured by intravascular ultrasound [ 9 ]. In another study presented at the European Society of Cardiology, the addition of evolocumab in 56 patients with dyslipidemia resulted in rapid and significant CIMT plaque reversal at six months interval [ 10 ]. Prior meta-analysis has shown for every 0.1mm increase in intimal thickness, the risk of myocardial infarction is increased by 10-15% [ 11 ], suggesting our patient who saw a mean intimal thickness reduction of 0.31mm had a marked mean risk reduction of 30-45%.…”